1. Sensitivity and specificity: clinical validation study of the SARS-CoV-2 Ab Rapid Test was conducted in 2020 in Shenzhen, China. 137 specimens from confirmed COVID-19 patients and 209 specimens from healthy individuals were tested. The kit demonstrated the sensitivity of 95.6% (131/137) and the specificity of 95.2% (199/209).

2. Samples were collected from COVID-19 confirmed cases with clinical symptoms, laboratory abnormalities or pulmonary imaging manifestations. No tests have been performed on specimens from latent infections or patients in the incubation period. It was observed that the detection rate of the kit was closely related to the time of disease onset, the kit showed higher positive detection rate in specimens from patients with delayed onset. Therefore, the interpretation of the test results should consider the specimen's collection time.

Clinical importance of combined RNA and antibody testing

COVID-19 serological markers dynamics (Total Ab/ IgM/ IgG):

  • 20%-40% of the patients developed antibodies on days 0-7 after onset

  • 60%~70% of the patients developed antibodies on days 8-11 after onset

  • > 90% of the patients had detectable levels of antibodies starting from day 12 after onset.

COVID-19 molecular markers dynamics (RNA):

  • RNA was detected in 60-75% of the patients on days 0-8 after onset RNA levels decrease to 40-50% starting from day 9 after onset

  • COVID-19 combined serological and molecular markers increases the sensitivity of diagnosis while maintaining the high specificity. Among the serological markers, total Ab detection has greater significance in clinical practice.

To register your interest or find out more about the rapid test kits, please fill in the form below and a Suretest representative will contact you shortly.

Sold under Life Clinic Australia.


© 2020 by Suretest Australia. All Rights Reserved.